- Home
- BKE vs TARS Comparison
BKE vs TARS Comparison
Compare BKE & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BKE | TARS |
|---|---|---|
| Founded | 1948 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.8B |
| IPO Year | 1992 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BKE | TARS |
|---|---|---|
| Price | $58.04 | $82.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $55.00 | ★ $76.56 |
| AVG Volume (30 Days) | ★ 460.1K | 419.7K |
| Earning Date | 11-21-2025 | 11-04-2025 |
| Dividend Yield | ★ 7.71% | N/A |
| EPS Growth | ★ 3.79 | N/A |
| EPS | ★ 4.09 | N/A |
| Revenue | ★ $1,277,894,000.00 | $366,100,000.00 |
| Revenue This Year | $8.24 | $147.24 |
| Revenue Next Year | $3.26 | $53.11 |
| P/E Ratio | $13.96 | ★ N/A |
| Revenue Growth | 4.67 | ★ 182.44 |
| 52 Week Low | $33.12 | $38.51 |
| 52 Week High | $61.69 | $85.25 |
Technical Indicators
Market Signals| Indicator | BKE | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 57.96 | 62.09 |
| Support Level | $55.60 | $78.10 |
| Resistance Level | $58.52 | $83.34 |
| Average True Range (ATR) | 1.46 | 3.12 |
| MACD | 0.14 | -0.33 |
| Stochastic Oscillator | 87.33 | 54.03 |
Price Performance
Historical ComparisonAbout BKE Buckle Inc. (The)
Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to affordable priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.